Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.31 is in line with its 5-year average of 1.31, around the middle of its 5-year range (-11.04–13.34).
As of the fiscal period ended Tuesday, June 30, 2026. 215.06% above its 12-month average of -1.14.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.31.
QUICK RATIO (ACID-TEST)
1.31
QUICK RATIO (ACID-TEST) AVG TTM
-1.14
QUICK RATIO (ACID-TEST) AVG 3Y
1.19
QUICK RATIO (ACID-TEST) AVG 5Y
1.31
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+215.06%
CURRENT VS 3Y AVG
+10.18%
CURRENT VS 5Y AVG
+0.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
-60.79%
vs the sector median at left
Lucid Diagnostics Inc.
Market Cap
$114.79M
Quick Ratio (Acid-Test)
1.31
TTM Avg
-1.14
3Y Avg
1.19
5Y Avg
1.31
Market Cap
$115.67M
Quick Ratio (Acid-Test)
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$113.89M
Quick Ratio (Acid-Test)
2.39
TTM Avg
3.50
3Y Avg
2.69
5Y Avg
1.97
Market Cap
$115.69M
Quick Ratio (Acid-Test)
11.47
TTM Avg
9.04
3Y Avg
10.96
5Y Avg
10.73
Market Cap
$113.77M
Quick Ratio (Acid-Test)
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$112.57M
Quick Ratio (Acid-Test)
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$112.27M
Quick Ratio (Acid-Test)
3.81
TTM Avg
1.94
3Y Avg
1.36
5Y Avg
2.38
Market Cap
$118.52M
Quick Ratio (Acid-Test)
13.31
TTM Avg
17.30
3Y Avg
10.78
5Y Avg
9.73
Market Cap
$118.90M
Quick Ratio (Acid-Test)
9.23
TTM Avg
4.04
3Y Avg
4.74
5Y Avg
7.63
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $114.79M | 1.31 | -1.14 | 1.19 | 1.31 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | 3.36 | 3.23 | 4.24 | 6.08 |
| Genelux Corporation (GNLX)vs › | $113.89M | 2.39 | 3.50 | 2.69 | 1.97 |
| MaxCyte, Inc. (MXCT)vs › | $115.69M | 11.47 | 9.04 | 10.96 | 10.73 |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | 13.40 | 10.04 | 7.53 | 8.95 |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | 6.49 | 6.44 | 8.52 | 8.53 |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.27M | 3.81 | 1.94 | 1.36 | 2.38 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.52M | 13.31 | 17.30 | 10.78 | 9.73 |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.90M | 9.23 | 4.04 | 4.74 | 7.63 |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.28M | 4.52 | 5.53 | 5.99 | 10.25 |
Quick Ratio
1.31
Excludes inventory
Current Ratio
1.33
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.31 |
| 2026-03-31 | 1.03 |
| 2025-12-31 | -11.04 |
| 2025-09-30 | 1.87 |
| 2025-06-30 | 1.12 |
| 2025-03-31 | 0.74 |
| 2024-12-31 | 1.05 |
| 2024-09-30 | 1.14 |
| 2024-06-30 | 1.71 |
| 2024-03-31 | 1.36 |
| 2023-12-31 | 0.74 |
| 2023-09-30 | 0.90 |
| 2023-06-30 | 1.34 |
| 2023-03-31 | 1.78 |
| 2022-12-31 | 2.88 |
| 2022-09-30 | 3.07 |
| 2022-06-30 | 4.52 |
| 2022-03-31 | 3.68 |
| 2021-12-31 | 13.34 |
| 2021-09-30 | 0.06 |
| 2021-06-30 | 0.16 |
| 2021-03-31 | 0.07 |
| 2020-12-31 | 0.04 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.06 |
| 2018-12-31 | 0.02 |
